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IL-17-producing cells have been shown to be important in the early stages of 
Mycobacterium tuberculosis (Mtb) infection in animal models. However, there are very 
little data on the role of IL-17 in human studies of tuberculosis (TB). We recruited TB 
patients and their highly exposed contacts who were further categorized based on results 
from an IFN-γ-release assay (IGRA): (1) IGRA positive (IGRA+) at recruitment (latently TB 
infected), (2) IGRA negative (IGRA−) at recruitment and 6 months [non-converters (NC)], 
and (3) IGRA− at recruitment and IGRA+ at 6 months (converters). Whole blood was 
stimulated with mycobacterial antigens and analyzed using T helper (Th) 17 multiplex 
cytokine assays. Th17, Vγ9Vδ2+, and CD161++Vα7.2+ mucosal-associated invariant 
T (MAIT) cells were analyzed by flow cytometry. The majority of IL-17 was produced by 
CD26+CD4+ Th17 cells (median 71%) followed by γδ T cells (6.4%) and MAIT cells (5.8%). 
TB patients had a significantly lower proportion of Th17 cells and CD4+CD161+Vα7.2+ 
cells producing both IL-17 and IFN-γ compared to LTBI subjects. IGRA NC had signifi-
cantly lower levels of CD26−CD4+ and CD8+ MAIT cells producing IL-17 compared to 
IGRA C but had significantly higher levels of IL-17A, IL-17F, IL-21, and IL-23 in ESAT-6/
CFP-10-stimulated supernatants compared to IGRA C. These data provide new insights 
into the role of IL-17 and IL-17-producing cells at three key stages of the Mtb infection 
spectrum.
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KeY POinTs
• Tuberculosis patients have fewer circulating CD4+CD161+Vα7.2+ cells producing both IFN-γ and 
IL-17 compared to latently infected individuals.
• Highly exposed contacts who remain uninfected had lower levels of circulating CD8+ mucosal- 
associated invariant T cell-producing IL-17 compared to those who become infected.
inTrODUcTiOn
Despite recent advances in tuberculosis (TB) diagnosis and treatment, it still remains a major 
infectious disease killer in resource-poor settings. In 2015, 10.4 million new cases were diagnosed 
resulting in 1.8 million deaths and over 50 million new infections (1). A major gap in knowledge for 
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development of new vaccines is an understanding of what consti-
tutes natural protective immunity. While there have been several 
insights through animal models, translation of these observations 
to humans is severely lacking, hampering the development of 
protective vaccines.
Interestingly, of the estimated 2–3 billion people infected with 
the causative pathogen, Mycobacterium tuberculosis (Mtb), only 
10% will develop active disease during their lifetime, while the 
remaining 90% are considered to be latently TB infected (LTBI). 
Thus, comparison of latently infected individuals with active 
TB cases may give some insight into factors that protect from 
development of disease, while analysis of individuals that remain 
tuberculin skin test (TST) or interferon-gamma release assay 
(IGRA) negative despite high exposure to TB may give some 
insight into factors that protect against initial infection. Studies 
have indicated a protective role for T helper (Th) 17 (2), mucosal-
associated invariant T (MAIT) (3), and γδ T cells (4) in TB, but 
this appears to depend on the stage of Mtb infection analyzed and 
whether mice or humans are studied.
Th17 cells have been implicated in the pathology of TB by 
inducing neutrophilic inflammation and mediating tissue 
damage (5). However, Th17 cells are capable of mediating both 
antimicrobial and pro-inflammatory responses, suggesting that 
their role during primary TB infection may be complex (5). 
Interestingly, a study analyzing TST+ vs TST− subjects showed a 
downregulation of IL-17, IL-23, and RORγt (a key transcription 
factor for Th17 cells) in TST+ individuals but no difference in 
Th1 and Th2 cytokines, suggesting that a paucity of Th17 cells 
either predisposes to or is a consequence of Mtb infection (6). In 
addition, circulating levels of IL-17 and IFN-γ have been shown 
to be lower in patients with active TB than in those with LTBI 
(7), again suggesting that the lack of IL-17 may either predispose 
to active TB disease or be a consequence of it. However, other 
studies have shown that dual production of IL-17 and IFN-γ 
from multifunctional Th17 cells correlates with disease severity 
(8). Thus, the role of Th17 cells during primary Mtb infection 
remains unclear.
Mucosal-associated invariant T  cells are the most abundant 
innate-like T cell in the human body, forming up to 5% of the 
human peripheral T  cell population (9). MAIT  cell depletion 
has recently been shown to increase the likelihood of developing 
severe bacterial infections (10). MAIT cells have a semi-invariant 
T cell receptor (TCR) alpha chain (Vα7.2), are restricted by the 
MHC-related protein 1, and are activated by cells infected with 
bacteria or yeast (3) and viruses (11). They express high levels of 
CD161 (c-type lectin) and have been shown to be reduced in the 
blood of patients and appear in the lung during active TB disease 
(3, 12).
γδ T  cells comprise 1–5% of peripheral blood lymphocytes 
(13, 14) and occur in a pre-activated differentiation state at high 
clonal frequencies, allowing for much faster responses com-
pared to other cell types (15). The invariant γδ TCR recognizes 
phospho-antigens originating from both the host and bacteria 
(16), and evidence of their contribution to the immune response 
against TB has grown steadily over the years (17). γδ T cells are 
well documented as an early source of IL-17 and IFN-γ follow-
ing a range of immune challenges (18, 19). In healthy adults, the 
major peripheral blood γδ T  cell subset expresses the Vγ9Vδ2 
TCR and displays pleiotropic features with IL-17(+) Vγ9Vδ2 
T  lymphocytes playing a role in inflammation during bacterial 
meningitis (20).
In this study, we investigated the Mtb antigen-specific produc-
tion of IL-17 family cytokines in TB patients and their exposed 
household contacts in Gambia and evaluated the cellular source 
of IL-17 using multiparameter flow cytometry.
MaTerials anD MeThODs
Participant information
Adults with smear positive (and culture-confirmed TB) were 
recruited following written informed consent and followed up to 
completion of treatment (standard regimen). Their TB-exposed 
household contacts were also recruited and analyzed for infec-
tion status using an in-house IGRA at baseline and 6 months 
from baseline. They were subsequently classified as IGRA 
converters (C) or non-converters (NC) (matched for exposure 
based on sleeping proximity to the index case and smear grade 
of the index case). Subjects who were IGRA+ at recruitment 
were defined as latently infected (LTBI). Venous blood samples 
were collected into heparinised vacutainers (Becton Dickinson, 
USA) and used for whole blood stimulation (for IGRA NC and 
C only) or separated into PBMC for flow cytometry analysis 
(all subjects). Only HIV-negative subjects were included in our 
analysis.
sample collection and Processing
Whole Blood Antigen Stimulation
450  µl whole blood was incubated with 50  µl of phosphate-
buffered saline (PBS) as a negative control (NIL) or with 50 µl 
of phytohemagglutinin (PHA; 5  µg/ml) as a positive control, 
purified protein derivative (PPD), final concentration 10 µg/ml 
(Staten Serum Institute, Denmark), or early secretory antigenic 
target 6, culture filtrate protein 10 fusion protein (ESAT-6/CFP-
10; EC; final concentration 10 µg/ml; kindly provided by Prof. T. 
Ottenhoff, Leiden University Medical Center, The Netherlands). 
Following overnight incubation at 37°C, 5% CO2, supernatant 
was collected and stored at −20°C prior to use.
Multiplex Cytokine Arrays
Multiplex immunoassays were carried out using the 15-plex Bio-
Plex Pro™ Human Th17 Cytokine Panel (Bio-Rad, CA, USA) 
according to the manufacturer’s instructions. Analytes measured 
were IL-1β, IL-4, IL-6, IL-10, IL-17A, IL-17F, IL-21, IL-22, 
IL-23, IL-25, IL-31, IL-33, IFN-γ, sCD40L, and TNF-α. Briefly, 
lyophilized standards were reconstituted, and serial dilutions 
were performed. Coupled beads were diluted in assay buffer, and 
50  µl was added to each well of the assay plate. Fifty microlit-
ers of diluted standards, blanks, samples (stimulated whole 
blood supernatants), and controls were added per well. Plates 
were then incubated at room temperature (RT), with shaking at 
350  rpm, for 30  min followed by three washes in wash buffer. 
Detection antibodies were diluted to 1 in 20 of their original 
concentration in detection antibody diluent and 25  µl added 
TaBle 1 | Participant information.
igra nc igra c lTBi active TB
N 11 10 10 10
Age, median (IQR) 27 (21–34) 29 (24–40) 21 (19–25) 29 (22–46)
Males, n (%) 3 (27) 1 (9) 2 (20) 9 (90)
IGRA, IFN-γ release assay; NC, non-converters; C, converters; TB, tuberculosis; LTBI, 
latent TB infection; IQR, interquartile range.
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to each well followed by another 30-min incubation. Following 
three washes, streptavidin-phycoerythrin (PE) was diluted to 1 in 
100 in assay buffer and 50 µl was added to each well. Plates were 
then incubated for 10 min and washed three times. 125 µl assay 
buffer was then added to each well and plates were briefly shaken 
and subsequently read using Magpix plate reader, with Bio-Plex 
Manager Software (version 6.1; Bio-Rad, Belgium). No significant 
differences were observed in background levels within or between 
groups. Thus, all cytokine responses for NIL-stimulated samples 
were subtracted from those for blood incubated with EC and PPD 
antigens.
Multiparameter Flow Cytometry
Cryopreserved PBMC samples were thawed and resuspended in 
RPMI + 10% FCS + 0.02% benzonase. After 6 h of rest, cells were 
counted and resuspended at 0.5–1.0 × 106 cells per test in 500 µl 
in polystyrene tubes and incubated at 37°C, 5% CO2 for 16–20 h 
with 1× cell stimulation cocktail plus protein transport inhibi-
tors (CSC; eBioscience, USA), containing phorbol 12-myristate 
13-acetate (PMA), ionomycin, brefeldin A, and monensin. 
Negative controls were incubated in the same conditions without 
the PMA but with a corresponding 1× protein transport inhibi-
tor cocktail (PTI; eBioscience, UK). After overnight stimula-
tion, tubes were centrifuged at 1,500  rpm for 5  min, and the 
supernatant was removed. Cells were incubated with Live/Dead 
Aqua (eBioscience, UK) for 10 min at RT in the dark. Cells were 
washed with 1 ml FACS buffer (PBS, 1% FCS, 0.2% Na Azide, 
0.1% EDTA) and centrifuged at 1,500 rpm for 5 min. Supernatant 
was removed, and a cell surface cocktail of anti-human CD3 
allophycocyanin (APC)-cyanine 7, CD8 Alexa Fluor 700, CD161 
PE, Vα7.2 APC (all from eBioscience, UK), and CD26- or Vγ9δ2 
TCR fluorescein isothiocyanate (kindly provided by Prof Dietrich 
Kabelitz, Kiel University, Germany) was added and incubated for 
15 min at 4°C. Cells were then washed in 1 ml FACS buffer and 
centrifuged at 1,500 rpm for 5 min; 150 µl of Cytofix/Cytoperm 
solution was added (Becton Dickinson, USA) and incubated for 
15 min at 4°C. Another wash step was performed, and cells were 
incubated with 1× Perm/Wash buffer (BD, USA) for 20 min at RT 
in the dark. Cells were washed and centrifuged at 1,800 rpm for 
5 min, supernatant removed and intracellular cytokine staining 
performed with IFN-γ PE-CF594 and IL-17 PE-cyanine 7 made 
up in 1× Perm/Wash buffer (all from BD, USA). Cells were incu-
bated for 30 min at RT, in the dark, washed once, and resuspended 
in 300 µl FACS buffer. 200,000 lymphocytes were acquired per 
sample using a LSR III Fortessa flow cytometer (BD Biosciences, 
USA) and BD FACSDiva software. Resultant FACS plots were 
analyzed using FlowJo (Version 10.1; Treestar, USA).
Data analysis
Data were analyzed using Prism v7 (GraphPad, CA, USA). 
Kruskal–Wallis test with Dunn’s post-test comparison (adjusted 
for multiple testing) was used to compare groups. Wilcoxon 
matched rank test was used to analyze within each group. 
Adjustment for age and sex was performed using logistic regres-
sion for data comparing TB with LTBI. However, no differences 
in results were observed with adjustment; thus all results are 
presented as unadjusted Mann–Whitney U-test values.
ethics statement
This study was carried out in accordance with the recommenda-
tions of the MRCG/Gambian government joint ethics committee 
with written informed consent from all subjects. All subjects gave 
written informed consent in accordance with the Declaration of 
Helsinki. The protocol was approved by the MRCG/Gambian 
government joint ethics committee.
resUlTs
characteristics of study Participants
A total of 41 subjects were included in this study: 11 IGRA NC, 
10 IGRA C, 10 LTBI, and 10 active TB (Table 1). The IGRA NC, 
IGRA C, and active TB were analyzed both at recruitment and 
6 months later. The LTBI were analyzed just at recruitment. The 
median ages for each group were comparable except the LTBI who 
were significantly younger than the other groups (p = 0.0126). 
In addition, while the majority of subjects were females in the 
IGRA NC, IGRA C, and LTBI groups; 90% of TB cases were males 
(p < 0.0001).
cD26+cD4+ Th17 cells are the Major 
il-17-Producing cells
CD26 has been shown to be a marker of Th17 cells (21). In all 
subject groups, the main source of IL-17 after PMA/ionomycin 
stimulation of purified PBMCs were CD26+ Th17 cells (p < 0.0001 
compared to all other subjects; Figures 1A,B), which accounted 
for 71% (63–80%) of all IL-17+ lymphocytes. γδ T  cells and 
MAIT cells accounted for 6.4% (1.3–14%) and 5.8% (3.0–10.7%) 
of IL-17+ cells, respectively (Figure 1A).
The proportion of Th17 cells was significantly higher among 
latently infected (LTBI) subjects than among those with active TB 
before (TB0) or after (TB6) treatment (p < 0.001 and p < 0.01, 
respectively; Figure  1C). Interestingly there was no significant 
difference in the proportion of Th17 cells between IGRA C and 
IGRA NC, but the proportion of CD4+CD26− IL-17+ cells was 
significantly higher in IGRA C compared to NC at baseline 
(p = 0.0279; Figure 1D).
il-17 and iFn-γ Dual-Producing Th cells
CD4+ T cells that co-express IL-17 and IFN-γ have been reported 
to be associated with TB disease severity (8) and are increased in 
certain autoimmune diseases (22). Although CD4+ T cells tended 
to produce only IFN-γ [median interquartile range (IQR) 37% 
(27–45%)] or only IL-17 [median (IQR) 4% (2–5%)] a propor-
tion of cells co-produced both cytokines [median (IQR) 1.2 
FigUre 1 | IL-17 producing cells in tuberculosis (TB) infection and  
disease. (a) Percentage of T helper 17 (Th17) cells, γδ T cells, and  
mucosal-associated invariant T (MAIT) cells within total IL-17+ cells (gated 
from lymphocytes). The majority of IL-17 was produced by Th17 cells. 
(B) Representative FACS plot of IL-17 production from CD26+ (Th17; upper 
right quadrant) and CD26− (lower right quadrant) CD4+ cells. (c) IL-17 
production from CD4+CD26− (left) and CD4+CD26+ (right) cells from TB cases 
before treatment (TB0) and after treatment (TB6) and latently TB infected 
(TST+). (D) IL-17 production from CD4+CD26− (left) and CD4+CD26+ (right) 
cells from IGRA non-converters (NC) and converters (C). Data were analyzed 
using Kruskal–Wallis test with Dunn’s post-test comparison (a,c) or 
Mann–Whitney U-test (D). Bar indicates median.
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(0.6–1.6%)] (Figure 2A). The proportion of cells producing only 
IFN-γ did not differ significantly between LTBI and active TB 
cases (LTBI vs TB0 or TB6) and was not affected by 6 months of TB 
treatment (TB0 vs TB6) (Figure 2B). However, the proportions of 
cells producing IL-17 alone or IL-17 in combination with IFN-γ 
were significantly higher in subjects with LTBI than in those with 
active TB (p < 0.01 and p < 0.001, respectively; Figures 2C,D). 
Although there was an increase in the median percentages of 
IL-17+ and IL-17+IFN-γ+CD4+ T cells after treatment of active TB 
(TB6 vs TB0) these differences were not statistically significant 
(Figures 2C,D). No differences in any subset were seen between 
IGRA NC and C (data not shown).
cD3lo but not cD3bright γδ T cells  
Produce il-17
IL-17(+) Vγ9Vδ2 T  lymphocytes have been shown to con-
tribute to inflammation during bacterial infections (23) and 
to respond preferentially to Mtb antigens (24). Therefore, we 
analyzed Vγ9δ2 T cells in TB cases and LTBI contacts and saw 
two distinct populations: CD3bright and CD3lo (Figure 3A). These 
CD3lo γδ T cells have previously been described as “NK-like” γδ 
T cells (25). No difference between TB cases and LTBI contacts 
was seen in the proportion of CD3loγδ cells, but LTBI subjects 
had a significantly higher proportion of CD3bright γδ T  cells 
compared to active TB patients (Figure  3B). Both CD3bright 
and CD3lo γδ T  cells were able to produce IFN-γ after PMA/
ionomycin stimulation, but IL-17 production both alone and 
in conjunction with IFN-γ was restricted to the CD3lo subset 
(Figure  3C). No significant difference was observed between 
TB cases and LTBI subjects in the proportions of Vγ9δ2 T cells 
producing either IFN-γ or IL-17 alone; however, a significantly 
lower proportion of CD3loγδTCR+IFN-γ+IL-17+ cells was 
seen in TB cases compared to LTBI (median [IQR] =  0.03% 
[0.00–0.21%] for active TB compared to 0.32% [0.05–1.18%] for 
LTBI; p = 0.0252; Figure 3D). No differences were seen between 
IGRA NC and C (data not shown).
Production of il-17 from  
Vα7.2+cD161+ cells
Invariant CD8+ cells have previously been implicated in protec-
tive immunity to TB (12). Thus, we analyzed differential expres-
sion of Vα7.2 and CD161 within both CD4+ and CD8+ T  cell 
subsets. Within the CD4+ subset, four distinct populations were 
evident: Vα7.2−CD161−, Vα7.2−CD161+, Vα7.2+CD161+, and 
Vα7.2+CD161− (Figure 4A). Within the CD8+ subset, five dis-
tinct populations were evident: Vα7.2−CD161−, Vα7.2−CD161+, 
Vα7.2+CD161++ (MAIT), Vα7.2+CD161+, and Vα7.2+CD161− 
(Figure  4B). We found no difference in the proportions of 
each of the phenotypic subsets between TB cases and LTBI or 
between IGRA C and NC (data not shown). However, when 
functionality was assessed, there was a significantly higher pro-
portion of CD4+Vα7.2+CD161+ cells producing both IL-17 and 
IFN-γ in LTBI compared to pre-treatment (p < 0.001) active TB 
cases (Figure  4C) but no difference between IGRA C and NC 
(Figure 4E). In addition, no difference was seen in TB cases com-
pared to LTBI (Figure 4D) but there was a significantly higher 
proportion of CD8+ MAIT cells producing IL-17 alone in IGRA 
C compared to NC (p = 0.0273; Figure 4F).
Differential Mtb-specific Production of 
Th17 Family cytokines in igra c and nc
Following overnight stimulation of whole blood with PPD, 
significantly higher concentrations of IL-17A, IL-17F, IL-21, and 
FigUre 2 | IFN-γ and IL-17 production from CD4+ T cells in tuberculosis (TB) infection and disease. (a) Representative FACS plot of IFN-γ and IL-17 production 
from CD4+ T cells. (B) % CD4+ cells producing IFN-γ alone in TB cases before and after treatment and in latently TB infected (from FACS plot top left quadrant).  
(c) % CD4+ cells producing both IFN-γ and IL-17 (from FACS plot top right quadrant). (D) % CD4+ cells producing IL-17 only (from FACS plot bottom right 
quadrant). Data were analyzed using Kruskal–Wallis test with Dunn’s post-test comparison. Bar indicates median.
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IL-23 were produced by recently infected IGRA C at 6 months 
compared to their preinfection (baseline) concentrations 
(p = 0.0016, p < 0.0001, p = 0.0006, and p = 0.0086, respectively) 
(Figure 5). No changes in PPD-induced cytokine concentrations 
were seen between baseline and 6 months for IGRA NC, and apart 
from significantly higher concentrations of IL-22 at 6 months in 
IGRA C compared to NC (p < 0.0001), there were no significant 
differences between the IGRA C and NC at either time point. 
There were no differences in IL-33 production either within or 
between groups (Figure 5).
Following overnight stimulation of whole blood with EC, con-
centrations of IL-17A, IL-17F, IL-21, and IL-23 were all signifi-
cantly higher in IGRA NC than IGRA C at baseline (p = 0.0113, 
p = 0.0008, p = 0.0004, and p = 0.0002, respectively; Figure 6). 
Cytokine concentrations did not differ between baseline and 
6 months for IGRA NC, but there were significant increases in 
concentrations of all four of these cytokines from baseline to 
6 months among IGRA C. Moreover, EC-specific IL-22 produc-
tion was observed only in IGRA C at 6 months, suggesting that 
EC-specific IL-22 is a biomarker of infection in some household 
contacts of TB cases. No differences in IL-33 concentrations were 
seen within or between groups.
DiscUssiOn
The role of IL-17 and its family members in protective immunity 
to TB remains unclear. In addition, while the role of IL-17-
producing cells, including Th17, MAIT, and γδ T cells has been 
extensively studied in mice, there are little data available in humans, 
particularly from West Africa. Therefore, in this study, we aimed 
to determine the role of soluble IL-17 and IL-17-producing cells 
at three key transition points in the Mtb infection spectrum: (i) 
after exposure to a TB case but prior to development of latent TB 
infection, (ii) after development of LTBI but prior to development 
of active TB disease, and (iii) before and after treatment of active 
TB disease. We found the main source of IL-17 was from CD26+ 
Th17  cells in all subjects. However, while secreted IL-17 levels 
were higher in TB-exposed IGRA NC, they had a lower propor-
tion of IL-17+ cells compared to IGRA C at baseline (i.e., prior 
to conversion/infection). In active TB patients, cellular levels of 
IL-17 were significantly lower than in LTBI.
We found relatively high levels of IFN-γ+IL-17+ dual-pro-
ducing CD4+ T cells across all participant groups. In a previous 
study of TB patients, accumulation of cells producing both Th1/
Th17 cytokines correlated with disease severity (8). However, we 
FigUre 3 | γδ T cells in tuberculosis (TB) infection and disease. (a) Representative FACS plot showing Vγ9δ2 TCR+ cells with low (lo) and bright CD3 expression. 
(B) Proportion of CD3bright and CD3lo γδ T cells from TB patients (white dots) and latently TB infected (LTBI) (gray dots). (c) Representative FACS plots of IFN-γ and 
IL-17 expression from CD3lo cells. (D) % IL-17+IFN-γ+γδ T cells from TB cases (TB0) and LTBI. Data were analyzed with Mann–Whitney U-test. Bar indicates median.
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saw significantly lower levels of IFN-γ+IL-17+ dual-producing 
invariant (Vα7.2+CD161+) CD4+ T cells and also IL-17+IFN-γ− 
Th17 cells in active TB compared to LTBI, suggesting that in our 
Gambian population, IL-17-producing CD4+ T cells either alone 
or in combination with IFN-γ have either migrated to the lung 
or are not pathogenic in our setting. Several studies have shown 
differential soluble and cellular cytokine production in active 
compared to LTBI (26–28). While levels are generally higher in 
active TB indicating a pathogenic effect [i.e., TNF-α (26), poly-
functional T cells (27)], in line with our findings, a study from 
Malawi showed higher soluble IL-17 in LTBI compared to active 
TB (28). One limitation of our study is that we used a polyclonal 
stimulant to induce IL-17 production, and thus, we may see dif-
ferences with Mtb antigen-specific stimulation, currently under 
investigation in our laboratory.
In highly TB-exposed contacts, those that converted to a 
positive IGRA by 6 months had a significantly higher propor-
tion of IL-17-producing CD4+CD26− cells compared to NC 
at baseline. These cells have been found to be abundant in 
autoimmune diseases, cancers, and also in reactive tissues (29), 
suggesting that they are potential inflammatory response mark-
ers in Mtb infection. Interestingly, we saw significantly lower 
levels of both cell types in active TB pretreatment compared 
to LTBI, supporting previous findings that IL-17 is increased 
during early Mtb infection (i.e., prior to disease progression). 
We saw no difference in the total proportion of CD4+ or 
CD8+CD161+Vα7.2+ cells in IGRA NC and C. However, similar 
to Th17 cells, the proportions of MAIT cells producing IL-17 
alone were also significantly lower in IGRA NC compared to 
IGRA C at baseline. This is possibly due to migration of cells 
from peripheral blood into the tissues but could not be deter-
mined in this study. Interestingly, we saw no CD4−CD8− double 
negative MAIT cells in our setting (data not shown), but we did 
see a distinct population of CD4+Vα7.2+CD161+ cells, which 
could potentially be germline-encoded mycolyl-reactive cells 
(30). Our study supports previous findings on production of 
IL-17 by MAIT  cells following PMA stimulation (31), which 
has not been seen in other African countries (Wong et  al., 
manuscript in preparation). This may be due to different Mtb 
strains or host genetics.
FigUre 4 | Functional Vα7.2+CD161+ cells in tuberculosis (TB) infection and disease. (a,B) Representative FACS plots for CD161 and Vα7.2 expression within 
CD4+ (a) and CD8+ (B) cells. Three defined CD4+ subsets and four defined CD8+ subsets (boxes) were analyzed for cytokine production (IL-17 and IFN-γ). 
Proportion of IL-17+IFN-γ+CD4+Vα7.2+CD161+ (c,e) and IL-17I+FN-g+ mucosal-associated invariant T cells (D,F) in TB cases before (TB0) and after treatment (TB6) 
and latently TB infected (c,D) and in IGRA non-converters (NC) and converters (C) (e,F). Data were analyzed using Kruskal–Wallis test (c,D) or Mann–Whitney 
U-test (e,F). Bar indicates median.
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In contrast to studies in mice (4), we found virtually no IL-17 
production from γδ T cells. Previous reports have shown that γδ 
T cells represent several distinct subsets, which may differ in the 
stimuli needed to bring about their response (32). Certainly, the 
majority of findings in healthy donors have observed that the 
predominant subset of γδ T cells present in the human peripheral 
blood, characterized by the expression of a Vγ9Vδ2 TCR, con-
tained very few (typically <1%) IL-17 producers (20). However, 
in bacterial meningitis, up to 60–70% of Vγ9Vδ2 T  cells were 
IL-17+ when cultured using Th17 polarizing conditions (20). 
Another report has shown that IL-17-producing γδ T  cells 
were significantly increased in TB patients compared to healthy 
donors (16), and studies in mice have shown that stimulation in 
IL-17-promoting conditions (i.e., exogenous IL-23) results in 
higher production of IL-17 from γδ T cells than from Th17 cells 
(32). Interestingly, no difference was seen in the proportion of 
“NK-like” γδ T cells (CD3lo) (25) between groups, but IL-17 pro-
duction both alone and in conjunction with IFN-γ was restricted 
FigUre 5 | Soluble IL-17 superfamily factors in IFN-γ-release assay (IGRA) converters (C) and non-converters (NC) following purified protein derivative (PPD) 
stimulation of whole blood. 15-plex Th17 cytokine profiles were analyzed following PPD stimulation of whole blood from IGRA NC and C at recruitment (white dots) 
and 6 months (gray dots). Showing IL-17A, IL-17F, IL-21, IL-22, IL-23, and IL-33. Data were analyzed using Kruskal–Wallis test followed by Dunn’s post-test 
comparison. Bar indicates median.
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to this subset unlike previous reports in mice showing IL-17 
production solely from CD3bright γδ T cells (33).
In IGRA NC, levels of soluble IL-17A, IL-17F, IL-21, and 
IL-23 in EC-stimulated blood were significantly higher at 
baseline than in IGRA C, suggesting production precedes early 
clearance of the pathogen, most likely through innate cells. In 
contrast, IL-22 was only detectable in participants who had 
recently converted to a positive IGRA test results. IL-22 is an 
effector cytokine of IL-17 that acts directly on the lung epithelia 
(34) and has been shown to inhibit growth of Mtb in human 
macrophages (35). This supports a protective role of IL-17 and 
IL-22 during early infection and suggests IL-22 as a potential 
marker of LTBI. It is important to note that our data on soluble 
mediators used whole blood stimulation with antigen-specific 
stimulation, while our cellular analysis used PBMC with poly-
clonal stimulation, suggesting that the inclusion of neutrophils 
and other innate cells in the stimulation may further promote 
IL-17 production. In addition, it suggests that production of 
IL-17 is cytokine mediated (i.e., through promotion of IL-22 
and IL-23) rather than TCR mediated.
In conclusion, these data provide new insights into the role 
of IL-17 and IL-17-producing cells in the pathogenesis of TB. 
Our findings suggest differential roles for IL-17-producing 
cells at distinct stages of the TB infection spectrum and can 
potentially be exploited for novel diagnostics and therapeutics. 
Future longitudinal studies will analyze responses following Mtb 
FigUre 6 | Soluble IL-17 superfamily factors in IFN-γ-release assay (IGRA) converters (C) and non-converters (NC) following ESAT-6/CFP-10 stimulation of whole 
blood. 15-plex Th17 cytokine profiles were analyzed following EC stimulation of whole blood from IGRA NC and C at recruitment (white dots) and 6 months (gray 
dots). Showing IL-17A, IL-17F, IL-21, IL-22, IL-23, and IL-33. Data were analyzed using Kruskal–Wallis test followed by Dunn’s post-test comparison. Bar indicates 
median.
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antigen-specific stimulation and using Th17-polarizing condi-
tions and will attempt to determine whether Th17  cells play a 
role in protection from TB infection and/or disease.
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